Literature DB >> 27564778

Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures.

Jinoos Yazdany1, Mark Robbins2, Gabriela Schmajuk3, Sonali Desai4, Diane Lacaille5, Tuhina Neogi6, Jasvinder A Singh7, Mark Genovese8, Rachel Myslinski9, Natalie Fisk9, Melissa Francisco9, Eric Newman10.   

Abstract

OBJECTIVE: Electronic clinical quality measures (eCQMs) rely on computer algorithms to extract data from electronic health records (EHRs). On behalf of the American College of Rheumatology (ACR), we sought to develop and test eCQMs for rheumatoid arthritis (RA).
METHODS: Drawing from published ACR guidelines, a working group developed candidate RA process measures and subsequently assessed face validity through an interdisciplinary panel of health care stakeholders. A public comment period followed. Measures that passed these levels of review were electronically specified using the quality data model, which provides standard nomenclature for data elements (category, datatype, and value sets) obtained through an EHR. For each eCQM, 3 clinical sites using different EHR systems tested the scientific feasibility and validity of measures. Measures appropriate for accountability were presented for national endorsement.
RESULTS: Expert panel validity ratings were high for all measures (median 8-9 of 9). Health system performance on the eCQMs was 53.6% for RA disease activity assessment, 69.1% for functional status assessment, 93.1% for disease-modifying antirheumatic drug (DMARD) use, and 72.8% for tuberculosis screening. Kappa statistics, which evaluated whether the eCQM validly captured data obtained from manual EHR chart review, demonstrated moderate to substantial agreement (0.54 for functional status assessment, 0.73 for tuberculosis screening, 0.84 for disease activity, and 0.85 for DMARD use).
CONCLUSION: Four eCQMs for RA have achieved national endorsement and are recommended for use in federal quality reporting programs. Implementation and further refinement of these measures is ongoing in the ACR's registry, the Rheumatology Informatics System for Effectiveness (RISE).
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27564778      PMCID: PMC5550019          DOI: 10.1002/acr.22984

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  36 in total

Review 1.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

3.  MDHAQ/RAPID3 scores: quantitative patient history data in a standardized "scientific" format for optimal assessment of patient status and quality of care in rheumatic diseases.

Authors:  Theodore Pincus; Isabel Castrejón
Journal:  Bull NYU Hosp Jt Dis       Date:  2011

4.  Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory.

Authors:  James F Fries; Eswar Krishnan; Matthias Rose; Bharathi Lingala; Bonnie Bruce
Journal:  Arthritis Res Ther       Date:  2011-09-14       Impact factor: 5.156

5.  Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set.

Authors:  Catherine H MacLean; Kenneth G Saag; Daniel H Solomon; Sally C Morton; Sarah Sampsel; John H Klippel
Journal:  Arthritis Rheum       Date:  2004-04-15

Review 6.  Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.

Authors:  Gabriela Schmajuk; Daniel H Solomon; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

7.  Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.

Authors:  Jinoos Yazdany; Chris Tonner; Gabriela Schmajuk; Grace A Lin; Amal N Trivedi
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

Review 8.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

9.  Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project.

Authors:  Michaela A Stoffer; Josef S Smolen; Anthony Woolf; Ales Ambrozic; Ailsa Bosworth; Loreto Carmona; Veronika Fialka-Moser; Estibaliz Loza; Pawel Olejnik; Ingemar F Petersson; Till Uhlig; Tanja A Stamm
Journal:  Ann Rheum Dis       Date:  2013-08-06       Impact factor: 19.103

10.  Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.

Authors:  Evo Alemao; Seongjung Joo; Hugh Kawabata; Maiwenn J Al; Paul D Allison; Maureen P M H Rutten-van Mölken; Michelle L Frits; Christine K Iannaccone; Nancy A Shadick; Michael E Weinblatt
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-03       Impact factor: 4.794

View more
  17 in total

1.  Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study.

Authors:  Julie Gandrup; Jing Li; Zara Izadi; Milena Gianfrancesco; Torkell Ellingsen; Jinoos Yazdany; Gabriela Schmajuk
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-01-09       Impact factor: 4.794

2.  2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis.

Authors:  Claire E H Barber; JoAnn Zell; Jinoos Yazdany; Aileen M Davis; Laura Cappelli; Linda Ehrlich-Jones; Donna Everix; J Carter Thorne; Victoria Bohm; Lisa Suter; Alex Limanni; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11-11       Impact factor: 4.794

3.  Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis.

Authors:  Jeffrey R Curtis; Lang Chen; Maria I Danila; Kenneth G Saag; Kathy L Parham; John J Cush
Journal:  J Rheumatol       Date:  2017-11-15       Impact factor: 4.666

4.  "Unspoken Questions": A Qualitative Study of Rheumatologists' Perspectives on the Clinical Implementation of Patient-reported Outcome Measures.

Authors:  Shanthini Kasturi; John B Wong; Lisa A Mandl; Timothy E McAlindon; Amy LeClair
Journal:  J Rheumatol       Date:  2020-07-01       Impact factor: 4.666

5.  Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic.

Authors:  Alfredo Aguirre; Laura Trupin; Mary Margaretten; Sarah Goglin; Jung Hee Noh; Jinoos Yazdany
Journal:  J Rheumatol       Date:  2020-02-15       Impact factor: 4.666

Review 6.  A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries.

Authors:  Chris Tonner; Gabriela Schmajuk; Jinoos Yazdany
Journal:  Curr Opin Rheumatol       Date:  2017-03       Impact factor: 5.006

Review 7.  Leveraging the electronic health record to improve quality and safety in rheumatology.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  Rheumatol Int       Date:  2017-08-29       Impact factor: 2.631

8.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

9.  RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Authors:  Gabriela Schmajuk; Jing Li; Michael Evans; Christine Anastasiou; Zara Izadi; Julia L Kay; Nevin Hammam; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2020-03-19       Impact factor: 5.532

10.  Significant Gains in Rheumatoid Arthritis Quality Measures Among RISE Registry Practices.

Authors:  Zara Izadi; Gabriela Schmajuk; Milena Gianfrancesco; Meera Subash; Michael Evans; Laura Trupin; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-12-27       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.